Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis.
作者信息
Anderhalten Lina, Wohlrab Felix, Paul Friedemann
机构信息
Experimental and Clinical Research Center, A Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
出版信息
Lancet Reg Health Eur. 2024 Aug 22;44:101023. doi: 10.1016/j.lanepe.2024.101023. eCollection 2024 Sep.
PMID:39444705
Abstract
摘要
相似文献
[1]
Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis.
Lancet Reg Health Eur. 2024-8-22
[2]
Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review.
Neurocrit Care. 2021-10
[3]
Potential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids.
ACS Chem Neurosci. 2024-3-20
[4]
[5]
[6]
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.
Brain Commun. 2021-10-12
[7]
[8]
[9]
Biofluid-based Biomarkers in Traumatic Brain Injury: A Narrative Review.
Brain Neurorehabil. 2024-3-18
[10]
Lessons from immunotherapies in multiple sclerosis.
Handb Clin Neurol. 2023
引用本文的文献
[1]
Brain-derived blood biomarkers in multiple sclerosis-current trends and beyond.
Front Immunol. 2025-6-16
本文引用的文献
[1]
[2]
[3]
[4]
[5]
[6]
[7]
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol. 2017-12-21
Zotero 插件